28137551|t|Bromocriptine Induces Autophagy -Dependent Cell Death in Pituitary Adenomas
28137551|a|Bromocriptine (BRC) is effective in patients with prolactinoma. However, the cytotoxic mechanism of BRC remains unknown. Slices for immunohistochemical pathology were randomly selected from 37 paraffin-embedded prolactinoma tissue sections. LC3 was detected by immunohistochemistry. GH3 and MMQ cells were treated by BRC and/or rapamycin (RAPA). Cell viability and the cell cycle were measured by CCK-8 and flow cytometry, respectively. Enzyme-linked immunosorbent assay measured prolactin secretion. Protein expression was detected by Western blot or immunofluorescence. LC3 was significantly expressed in prolactinoma in which patients were treated exclusively with BRC. LC3 expression was negative in normal tissues and prolactinoma in which patients were not treated with BRC. Treatment with 60 μM BRC for 24 hours induced cell death in MMQ cells by up to 50%. However, 110 μM BRC was required to produce a similar effect in GH3 cells. The cell cycle was arrested at the G0 - G1 phase and S phase. As the concentration and time increased, the conversion ratio of LC3-I to LC3-II increased and prolactin secretion decreased. In addition, Bcl-2 and BAX expression was decreased. The cell viability, prolactin level, and G0-G1 cells are similar in MMQ cells treated with RAPA and a low concentration of BRC and MMQ cells treated with a high concentration of BRC. Compared with the effects of a high concentration of BRC, treatment with RAPA and a low concentration of BRC effectively increase the conversion rate of LC3-I to LC3-II. BRC - treated pituitary adenoma cells mainly underwent autophagic cell death rather than apoptosis.
28137551	0	13	Bromocriptine	T109,T121	C0006230
28137551	14	21	Induces	T169	C0205263
28137551	22	31	Autophagy	T043	C0004391
28137551	43	53	Cell Death	T043	C0007587
28137551	57	75	Pituitary Adenomas	T191	C0032000
28137551	76	89	Bromocriptine	T109,T121	C0006230
28137551	91	94	BRC	T109,T121	C0006230
28137551	99	108	effective	T080	C1704419
28137551	112	120	patients	T101	C0030705
28137551	126	138	prolactinoma	T191	C0033375
28137551	153	162	cytotoxic	T169	C1511636
28137551	163	172	mechanism	T169	C0441712
28137551	176	179	BRC	T109,T121	C0006230
28137551	208	227	immunohistochemical	T059	C1441616
28137551	228	237	pathology	T091	C0030664
28137551	269	306	paraffin-embedded prolactinoma tissue	T024	C1519524
28137551	317	320	LC3	T116,T123	C2003747
28137551	325	333	detected	T033	C0442726
28137551	337	357	immunohistochemistry	T060	C0021044
28137551	359	362	GH3	T025	C0229535
28137551	367	376	MMQ cells	T025	C0229535
28137551	382	389	treated	T169	C1522326
28137551	393	396	BRC	T109,T121	C0006230
28137551	404	413	rapamycin	T109,T195	C0072980
28137551	415	419	RAPA	T109,T195	C0072980
28137551	422	436	Cell viability	T043	C0007620
28137551	445	455	cell cycle	T043	C0007586
28137551	473	478	CCK-8	T062	C2986858
28137551	483	497	flow cytometry	T059	C0016263
28137551	513	546	Enzyme-linked immunosorbent assay	T059	C0014441
28137551	556	575	prolactin secretion	T043	C2611224
28137551	577	595	Protein expression	T045	C1171362
28137551	600	608	detected	T033	C0442726
28137551	612	624	Western blot	T059,T063	C0005863
28137551	628	646	immunofluorescence	T059	C0079603
28137551	648	651	LC3	T116,T123	C2003747
28137551	670	679	expressed	T045	C1171362
28137551	683	695	prolactinoma	T191	C0033375
28137551	705	713	patients	T101	C0030705
28137551	719	726	treated	T169	C1522326
28137551	744	747	BRC	T109,T121	C0006230
28137551	749	763	LC3 expression	T045	C1171362
28137551	768	776	negative	T033	C0205160
28137551	780	786	normal	T080	C0205307
28137551	787	794	tissues	T024	C0040300
28137551	799	811	prolactinoma	T191	C0033375
28137551	821	829	patients	T101	C0030705
28137551	839	851	treated with	T061	C0332293
28137551	852	855	BRC	T109,T121	C0006230
28137551	857	866	Treatment	T061	C0087111
28137551	878	881	BRC	T109,T121	C0006230
28137551	889	894	hours	T079	C0439227
28137551	895	902	induced	T169	C0205263
28137551	903	913	cell death	T043	C0007587
28137551	917	926	MMQ cells	T025	C0229535
28137551	957	960	BRC	T109,T121	C0006230
28137551	995	1001	effect	T080	C1280500
28137551	1005	1014	GH3 cells	T025	C0229535
28137551	1020	1030	cell cycle	T043	C0007586
28137551	1035	1043	arrested	T043	C1155873
28137551	1051	1053	G0	T045	C0079394
28137551	1056	1064	G1 phase	T043	C1155840
28137551	1069	1076	S phase	T043	C1155869
28137551	1085	1098	concentration	T081	C1446561
28137551	1103	1107	time	T079	C0040223
28137551	1108	1117	increased	T081	C0205217
28137551	1123	1139	conversion ratio	T081	C0456603
28137551	1143	1148	LC3-I	T116,T123	C2003747
28137551	1152	1158	LC3-II	T116,T123	C2003747
28137551	1159	1168	increased	T081	C0205217
28137551	1173	1192	prolactin secretion	T043	C2611224
28137551	1193	1202	decreased	T081	C0547047
28137551	1217	1222	Bcl-2	T116,T123	C0293686
28137551	1227	1230	BAX	T116,T123	C0219474
28137551	1231	1241	expression	T045	C1171362
28137551	1246	1255	decreased	T081	C0547047
28137551	1261	1275	cell viability	T043	C0007620
28137551	1277	1292	prolactin level	T034	C0428411
28137551	1298	1309	G0-G1 cells	T025	C1988243
28137551	1325	1334	MMQ cells	T025	C0229535
28137551	1335	1347	treated with	T061	C0332293
28137551	1348	1352	RAPA	T109,T195	C0072980
28137551	1359	1362	low	T080	C0205251
28137551	1363	1376	concentration	T081	C1446561
28137551	1380	1383	BRC	T109,T121	C0006230
28137551	1388	1397	MMQ cells	T025	C0229535
28137551	1398	1410	treated with	T061	C0332293
28137551	1413	1417	high	T080	C0205250
28137551	1418	1431	concentration	T081	C1446561
28137551	1435	1438	BRC	T109,T121	C0006230
28137551	1458	1465	effects	T080	C1280500
28137551	1471	1475	high	T080	C0205250
28137551	1476	1489	concentration	T081	C1446561
28137551	1493	1496	BRC	T109,T121	C0006230
28137551	1498	1507	treatment	T061	C0087111
28137551	1513	1517	RAPA	T109,T195	C0072980
28137551	1524	1527	low	T080	C0205251
28137551	1528	1541	concentration	T081	C1446561
28137551	1545	1548	BRC	T109,T121	C0006230
28137551	1549	1560	effectively	T080	C1280500
28137551	1561	1569	increase	T081	C0205217
28137551	1574	1589	conversion rate	T081	C1521828
28137551	1593	1598	LC3-I	T116,T123	C2003747
28137551	1602	1608	LC3-II	T116,T123	C2003747
28137551	1610	1613	BRC	T109,T121	C0006230
28137551	1616	1623	treated	T169	C1522326
28137551	1624	1641	pituitary adenoma	T191	C0032000
28137551	1642	1647	cells	T025	C0334227
28137551	1665	1675	autophagic	T043	C0004391
28137551	1676	1686	cell death	T043	C0007587
28137551	1699	1708	apoptosis	T043	C0162638